pazufloxacin

Also Known As:

10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido(1,2,3-d,e)(1,4)benzoxazinecarboxylic acid; T 3761; T-3761; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-

Networked: 48 relevant articles (9 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - pazufloxacin: 48
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        pazufloxacin: 48

Experts

1.	Mitsuyama, Junichi: 2 articles (07/2005 - 06/2003)
2.	Ando, Masaru: 1 article (06/2018)
3.	Kadota, Jun-Ichi: 1 article (06/2018)
4.	Masuda, Taiki: 1 article (06/2018)
5.	Miyazaki, Eishi: 1 article (06/2018)
6.	Nureki, Shin-Ichi: 1 article (06/2018)
7.	Yamasue, Mari: 1 article (06/2018)
8.	Huang, Zhi-Xuan: 1 article (03/2018)
9.	Xu, Zhu-Ping: 1 article (03/2018)
10.	Zeng, Zhi-Bing: 1 article (03/2018)

Related Diseases

1.	Infections 05/01/2012 - "The purpose of this study is to evaluate the incidence of postimplant infections in patients who receive antimicrobial prophylaxis with pazufloxacin (PZFX). " 01/01/1995 - "Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections." 03/01/1993 - "The activities of T-3761 were lower than those of tosufloxacin against gram-positive bacterial systemic and pulmonary infections in mice but not against infections with methicillin-resistant Staphylococcus aureus. " 05/01/1999 - "In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients." 10/01/2005 - "These findings suggest that prulifloxacin, pazufloxacin and biapenem, which are newly introduced, are clinically effective in the treatment of infection caused with P. "
2.	Urethritis 03/01/1998 - "The results obtained in this study suggest that a high prevalence of fluoroquinolone-resistant gonococcal isolates with the Ser-91-to-Phe mutation in GyrA reduced the efficacy of pazufloxacin as treatment for gonococcal urethritis." 03/01/1998 - "Forty-two men with gonococcal urethritis were treated with an oral dosage of 200 mg of pazufloxacin, a new fluoroquinolone, three times daily for 3 days. "
3.	Legionnaires' Disease (Legionnaire's Disease) 06/01/2005 - "Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate." 06/01/2005 - "We report here a case of culture-proven Legionnaires' disease successfully treated with intravenous injection of pazufloxacin mesilate (PZFX), a fluoroquinolone newly approved in Japan. "
4.	Pneumonia (Pneumonitis) 12/01/2017 - "Importantly, the 2000 mg daily regimen of pazufloxacin produced a profile sufficient to have an antibacterial effect in prostate tissue against clinical isolates of Escherichia coli and Klebsiella pneumonia with MIC values less than 2 mg/L." 10/01/2010 - "In vivo efficacy of sivelestat in combination with pazufloxacin against Legionella pneumonia." 01/01/2012 - "For pneumonia, ceftriaxone and pazufloxacin were administered. " 05/01/2009 - "Legionella pneumonia was diagnosed as a consequence of the urinary examination performed for Legionella antigen detection; further, we initiated intravenous pazufloxacin administration. "
5.	Coinfection 03/01/1998 - "These results suggest that pazufloxacin would be useful for the treatment of polymicrobial infections, especially adnexitis." 03/01/1998 - "Therapeutic effects of an injectable new quinolone, pazufloxacin, against polymicrobial infections in the uterine endometritis model."

Related Drugs and Biologics

1.	Fluoroquinolones
2.	Mesylates (Mesylate)
3.	Levofloxacin (Levaquin)
4.	tosufloxacin
5.	Amphotericin B (Amphotericin)
6.	Imipenem Drug Combination Cilastatin (Primaxin)
7.	prulifloxacin
8.	sivelestat
9.	biapenem (L 627)
10.	pazufloxacin

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Intravenous Administration
4.	Oral Administration
5.	Transurethral Resection of Prostate (TURP)